Influence on the bioavailability of pharmaceutical components using nanotechnology formulations
- In: S3 - Improving bioavailability/bioequivalence on Tuesday, 4 September 2007, 9:00-12:00
- At: Beijing (China) (2007)
- Type: Presentation
- By: QIANG, Zhang (Peking University, Beijing, China)
A large number of new drug candidates in laboratories take enormous money and extensive labors every year, but just a minority of these candidates can be finally used in clinical therapeutics. One of the most important reasons is due to the fact that the bioavailability of these agents is too low to create activities in vivo although they might.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.